AstraZeneca Plc grew revenue by 41% to $37.4 billion in 2021, achieving significant increases across its four business sectors and in nearly all geographies except China where drug prices came under pressure. The top-line figure includes nearly $4 billion in revenue from the company’s Covid-19 vaccine, Vaxzevria, as well as $3.1 billion from drugs for rare diseases generated by the recent acquisition of Alexion Pharmaceuticals.
In the fourth quarter, revenue was $12 billion, up by 62%.